scholarly journals Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa

PLoS ONE ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. e32144 ◽  
Author(s):  
Julie H. Levison ◽  
Catherine Orrell ◽  
Sébastien Gallien ◽  
Daniel R. Kuritzkes ◽  
Naishin Fu ◽  
...  
2018 ◽  
Vol 36 ◽  
pp. e4-e5
Author(s):  
Muhammad Faisal Putro Utomo ◽  
Petrus Kanisius Yogi Hariyanto ◽  
Anindia Reina Yolanda ◽  
Nur Rizky Amaliah ◽  
Ni Made Dewi Dian Sukmawati ◽  
...  

2013 ◽  
Vol 32 (6) ◽  
pp. 644-647 ◽  
Author(s):  
Catherine Orrell ◽  
Julie Levison ◽  
Andrea Ciaranello ◽  
Linda-Gail Bekker ◽  
Daniel R. Kuritzkes ◽  
...  

2016 ◽  
Vol 21 (9) ◽  
pp. 1131-1137 ◽  
Author(s):  
Matthew P. Fox ◽  
Rebecca Berhanu ◽  
Kim Steegen ◽  
Cindy Firnhaber ◽  
Prudence Ive ◽  
...  

2012 ◽  
Vol 13 (3) ◽  
pp. 134-137 ◽  
Author(s):  
D Evans ◽  
M Maskwe ◽  
C Heneger ◽  
I Sanne

In South Africa, abacavir (ABC) is currently recommended as part of first- and second-line antiretroviral therapy (ART) for HIV-positive paediatric patients. Concerns about overprescribing of the drug, particularly to adults, led to an analysis of ABC use in public sector ART programmes. We investigated current prescription of the drug to adults and children accessing ART in 4 public sector programmes across Gauteng Province, South Africa. ABC was almost exclusively prescribed to children initiating ART and adults requiring regimen changes due to drug toxicities. Patterns of ABC use among HIV-positive paediatric patients followed national ART treatment guidelines on the application of the drug. Although ABC is commonly used in the private sector for adults, the current national ART treatment guidelines for adults and adolescents should include ABC as an alternative to standard first- or second-line ART.


Sign in / Sign up

Export Citation Format

Share Document